Archive

  • The Role Of SGLT Inhibitors In Heart Failure Beyond Glycemic Control A Review
  • Department of Pharmacy Practice, K. K. College of Pharmacy, Gerugambakkam, Tamil Nadu.

Abstract

This article provides an in-depth overview of heart failure (HF) and the recently approved SGLT2 inhibitor, sotagliflozin, emphasizing its efficacy in treating adults with HF, type 2 diabetes, chronic kidney disease, and cardiovascular risk factors. The SOLOIST study is discussed, demonstrating the significant reduction in cardiovascular fatalities, hospitalizations, and urgent visits for heart failure with sotagliflozin use. The mechanism of action of SGLT2 inhibitors in HF, chronic kidney disease (CKD), and type 2 diabetes mellitus (T2DM) is explored, highlighting their direct renal effects, indirect benefits, and cardiovascular advantages. The article concludes by emphasizing the multifaceted benefits of SGLT2 inhibition beyond glycemic control, including weight reduction, blood pressure management, and cardiovascular risk reduction. It advocates for SGLT2 inhibitors as the preferred therapy for patients with both T2DM and HF, suggesting potential expansion to all HF patients, irrespective of glycemic status, pending ongoing trials. Overall, the article underscores the pivotal role of SGLT2 inhibitors in improving clinical outcomes and longevity in individuals with HF and related comorbidities.

Keywords

Heart Failure, T2DM, SGLT2 inhibitors, sotagliflozin.

Reference

  1. Kim AH, Jang JE, Han J. Current status on the therapeutic strategies for heart failure and diabetic cardiomyopathy. Biomedicine & Pharmacotherapy. 2022; 145: 1-14.
  2. Chentli F, Azzoug S, Mahgoun S. Diabetes mellitus in elderly. Indian journal of endocrinology and metabolism. 2015; 19(6): 744-752.
  3. Rosano GM, Vitale C, Seferovic P. Heart failure in patients with diabetes mellitus. Cardiac failure review. 2017; 3(1): 52 – 55.
  4. Santos-Ferreira D, Gonçalves-Teixeira P, Fontes-Carvalho R. SGLT-2 inhibitors in heart failure and type-2 diabetes: hitting two birds with one stone? Cardiology. 2020; 145(5): 311-320.
  5. Nikolic M, Zivkovic V, Jovic JJ, Sretenovic J, Davidovic G et al. SGLT2 inhibitors: a focus on cardiac benefits and potential mechanisms. Heart Failure Reviews. 2021; 3:1-5.
  6. Cowie MR, Fisher M. SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control. Nature Reviews Cardiology. 2020; 17(12): 761-772.
  7. Lopaschuk GD, Verma S. Mechanisms of cardiovascular benefits of sodium-glucose co-transporter 2 (SGLT2) inhibitors: a state-of-the-art review. Basic to Translational Science. 2020; 5(6): 632-644.
  8. Genuardi MV, Mather PJ. The dawn of the four-drug era? SGLT2 inhibition in heart failure with reduced ejection fraction. Therapeutic Advances in Cardiovascular Disease. 2021; 15: 1-12.
  9. Muscoli S, Barillà F, Tajmir R, Meloni M, Della Morte D, Bellia A, Di Daniele N, Lauro D, Andreadi A. The new role of SGLT2 inhibitors in the management of heart failure: current evidence and future perspective. Pharmaceutics. 2022; 14(8): 17-30.
  10. Bhatt DL, Szarek M, Steg PG, Cannon CP, Leiter LA, McGuire DK, Lewis JB, Riddle MC, Voors AA, Metra M, Lund LH. Sotagliflozin in patients with diabetes and recent worsening heart failure. New England Journal of Medicine. 2021; 384(2): 117-128.
  11. Skrabic R, Kumric M, Vrdoljak J, Rusic D, Skrabic I, Vilovic M, et.al  SGLT2 inhibitors in chronic kidney disease: from mechanisms to clinical practice. Biomedicines. 2022; 10(10): 24-58.    
  12. Smith A. Investigating SGLT2 Inhibitors in Heart Failure. US Pharm. 2023; 48(3): 45-48.
  13. Martins CN, Bau AA, Silva LM. Possible Mechanisms of Action of SGLT2 Inhibitors in Heart Failure. ABC Heart Fail Cardiomyop. 2021; 1(1): 33-43.  
  14. Vallon V. The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus. Annual review of medicine. 2015; 66: 255-270.

image
M. Madhumitha
Corresponding author

Department of pharmacy practice, K. K. College of Pharmacy

image
S. Nivetha
Co-author

Department of pharmacy practice, K. K. College of Pharmacy

image
J. Ashwini
Co-author

Department of pharmacy practice, K. K. College of Pharmacy

M. Madhumitha*, J. Ashwini, S. Nivetha, The Role Of SGLT Inhibitors In Heart Failure Beyond Glycemic Control: A Review, Int. J. in Pharm. Sci., 2023, Vol 1, Issue 12, 659-669.https://doi.org/10.5281/zenodo.10427940

More related articles
An Overview on Artificial Blood...
Rajnandini Ahire, Mukesh Ratnaparkhi, Shital Kshirsagar, Devang M...
Formulation And In vitro Evaluation Of Bilayer Tab...
Mayur Aware, Sheetal Gondkar, Rishikesh Bachhav, ...
A Comprehensive Review On Herbal Plants Showing An...
Saurabh Dumbre, Gaurav Gawade, Swati Jadhav, Pravin Khamkar, ...
Gastroretentive Drug Delivery System : A Review...
Suraj Kothule, Smita Aher, Rishikesh Bachhav, ...
Bilayer Floating Tablet : A Novel Floating Tablet...
Mayur Aware, Sheetal Gondkar, Rishikesh Bachhav, ...
Related Articles
Ayurvedic Remedies of Bacterial Meningitis...
Komal Ushir, Dinesh Rishipathak, Pragati Bhosale, Manisha Raut, ...
More related articles
An Overview on Artificial Blood...
Rajnandini Ahire, Mukesh Ratnaparkhi, Shital Kshirsagar, Devang Mahale, ...
A Comprehensive Review On Herbal Plants Showing Anti Diabetic Activity...
Saurabh Dumbre, Gaurav Gawade, Swati Jadhav, Pravin Khamkar, ...
An Overview on Artificial Blood...
Rajnandini Ahire, Mukesh Ratnaparkhi, Shital Kshirsagar, Devang Mahale, ...
A Comprehensive Review On Herbal Plants Showing Anti Diabetic Activity...
Saurabh Dumbre, Gaurav Gawade, Swati Jadhav, Pravin Khamkar, ...